Granahan Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Granahan Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.11M	Buy	220,600 +22,293	+11%	+$369K	0.2%	113
2025 Q4	$2.61M	Buy	+198,307	New	+$2.34M	0.11%	136
2025 Q3	–	Sell	-80,362	Closed	-$3.79M	–	157
2025 Q2	$3.79M	Sell	80,362 -61,858	-43%	-$2.52M	0.15%	113
2025 Q1	$5.56M	Buy	142,220 +5,782	+4%	+$249K	0.28%	90
2024 Q4	$7.39M	Sell	136,438 -36,196	-21%	-$1.85M	0.31%	83
2024 Q3	$8.7M	Sell	172,634 -111,015	-39%	-$5.2M	0.34%	89
2024 Q2	$12.5M	Buy	283,649 +67,833	+31%	+$2.87M	0.5%	64
2024 Q1	$10.8M	Buy	215,816 +89,044	+70%	+$4.83M	0.38%	78
2023 Q4	$7.66M	Buy	126,772 +42,210	+50%	+$2.18M	0.25%	103
2023 Q3	$4.82M	Buy	84,562 +12,628	+18%	+$697K	0.17%	128
2023 Q2	$3.67M	Sell	71,934 -1,703	-2%	-$45.8K	0.11%	141
2023 Q1	$1.58M	Buy	+73,637	New	+$1.24M	0.05%	157

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granahan Investment Management's MLTX Position: Q1 2026 in Review

Granahan Investment Management increased its MoonLake Immunotherapeutics (MLTX) stake by 11% in Q1 2026, buying an estimated $369K and bringing the position to 220,600 shares worth $4.11M. The position accounts for 0.2% of the portfolio, ranked #113.

Granahan Investment Management first reported a position in MLTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $12.5M in Q2 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Granahan Investment Management held 220,600 shares of MoonLake Immunotherapeutics worth $4.11M as of Q1 2026.
Granahan Investment Management bought 22,293 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $369K.
MoonLake Immunotherapeutics made up 0.2% of Granahan Investment Management's portfolio in Q1 2026, its #113 holding.
Granahan Investment Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 12 quarters since.
Granahan Investment Management's MoonLake Immunotherapeutics position peaked at $12.5M in Q2 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.